Study Name:
Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Targeted Disease(s):
COPD|Other
Purpose of Study:
This clinical trial is evaluating if MK-5475 is effective, safe, and tolerated in adults with PH-COPD.
Study Dates:
March 16, 2023 - August 26, 2025
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Merck & Co., Inc.
Contact:
Phone: 1-888-577-8839
Email: [email protected]
ClinicalTrails.gov Identifier:
NCT05612035
